La Jolla Interdisciplinary Neuroscience Center Cores

拉霍亚跨学科神经科学中心核心

基本信息

项目摘要

The overall goal of this interinstitutional NINDS P30 Core Grant is to foster new interdisciplinary collaborations among neuroscientists in La Jolla institutions by allowing access to scientific cores to which they were previously denied or had little access, and by promoting new cores to promote state-of-the-art technology; these cores were started under the prior auspices of the NIH Blueprint Core Grant (P30 NS057096) that was awarded to the PI, Dr. Lipton, for the past five years. Since the entire Blueprint Core Grant Program has been terminated by NIH, NINDS Program Officials asked us to submit this NINDS P30 Core Grant. To accomplish our goal, we have chosen among the very best core facilities on the Blueprint Core Grant, and have chosen top scientists to run these cores at the Sanford-Burnham Medical Research Institute (SBMIR) and the University of California San Diego (UCSD) in order to assist NINDS neuroscientists in La Jolla. The cores proposed here represent (i) High-Throughput (HS) Library Screening (at SBMRI), (ii) Neuropathology (at UCSD), and (iii) Electrophysiology (at SBMIR with Advisors at Salk), in addition to (iv) an Administrative Core (centered at SBMRI). These Core Facilities will be available to neuroscientists at all four institutions on the La Jolla Torrey Pines Mesa, composed of SBMRI, UCSD, Salk, and The Scripps Research Institute. These institutions share one of the top-rated neuroscience graduate programs in the country and have committed considerable institutional funds towards these cores. This work is aimed at developing new treatments for neurological disorders. The Specific Aims, which will be facilitated by all 3 Scientific Cores and the Administrative Core, are as follows: 1. To obtain Core support for Neuroscientists studying Neurodegenerative Disorders. The Cores will also help develop Neuroprotective Therapies. These disorders, represented in the Qualifying NINDS Projects of Major USERS, include Alzheimer's, Parkinson's, ALS, and Huntington's disease. 2. To obtain Core support for Neuroscientists studying Neoplastic Disorders of the brain. These disorders, represented in the Qualifying NINDS Projects of Major USERs, include glioblastoma multiforme and medulloblastoma tumors. 3. To obtain Core support for Neuroscientists studying Developmental Disorders. Disorders include abnormal neuronal migration, and are represented in NINDS Qualifying Projects of Major USERs.
该跨机构NINDS P30核心赠款的总体目标是通过允许访问他们以前被拒绝或很少访问的科学核心,并通过促进新的核心来促进最先进的技术,从而促进拉霍亚机构的神经科学家之间新的跨学科合作;这些核心是在NIH蓝图核心资助(P30 NS 057096)的先前赞助下开始的,该资助在过去五年中授予PI Lipton博士。由于整个蓝图核心补助金计划已被NIH终止,NINDS计划官员要求我们提交此NINDS P30核心补助金。为了实现我们的目标,我们选择了蓝图核心补助金中最好的核心设施,并选择了顶级科学家在桑福德-伯纳姆医学研究所(SBMIR)和加州圣地亚哥大学(UCSD)运行这些核心,以协助拉霍亚的NINDS神经科学家。这里提出的核心代表(i)高通量(HS)库筛选(在SBMRI),(ii)神经病理学(在UCSD),和(iii)电生理学(在SBMIR与顾问在索尔克),除了(iv)行政核心(以SBMRI为中心)。这些核心设施将提供给拉霍亚托里松树梅萨的所有四个机构的神经科学家,包括SBMRI,UCSD,Salk和斯克里普斯研究所。这些机构共享全国最高评级的神经科学研究生课程之一,并已承诺对这些核心相当大的机构资金。这项工作旨在开发神经系统疾病的新疗法。具体目标将由所有三个科学核心和行政核心推动,具体目标如下: 1.为研究神经退行性疾病的神经科学家获得核心支持。核心还将帮助开发神经保护疗法。这些疾病在主要用户的合格NINDS项目中有代表性,包括阿尔茨海默氏症、帕金森氏症、ALS和亨廷顿氏病。 2.为研究大脑肿瘤性疾病的神经科学家获得核心支持。这些疾病在主要用户的合格NINDS项目中有代表性,包括多形性胶质母细胞瘤和髓母细胞瘤。 3.为研究发育障碍的神经科学家获得核心支持。疾病包括异常的神经元迁移,并在NINDS主要用户的资格项目中表示。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STUART A LIPTON其他文献

STUART A LIPTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STUART A LIPTON', 18)}}的其他基金

Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's disease
阿尔茨海默病中先天免疫人类小胶质细胞和适应性免疫 Tregs 之间的串扰
  • 批准号:
    10686979
  • 财政年份:
    2022
  • 资助金额:
    $ 87.2万
  • 项目类别:
Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's disease
阿尔茨海默病中先天免疫人类小胶质细胞和适应性免疫 Tregs 之间的串扰
  • 批准号:
    10515987
  • 财政年份:
    2022
  • 资助金额:
    $ 87.2万
  • 项目类别:
Leadership in AD/ADRD Drug Discovery
AD/ADRD 药物发现领域的领导地位
  • 批准号:
    10193424
  • 财政年份:
    2021
  • 资助金额:
    $ 87.2万
  • 项目类别:
Leadership in AD/ADRD Drug Discovery
AD/ADRD 药物发现领域的领导地位
  • 批准号:
    10687169
  • 财政年份:
    2021
  • 资助金额:
    $ 87.2万
  • 项目类别:
Leadership in AD/ADRD Drug Discovery
AD/ADRD 药物发现领域的领导地位
  • 批准号:
    10461746
  • 财政年份:
    2021
  • 资助金额:
    $ 87.2万
  • 项目类别:
Pro-Electrophilic Drugs PEDs for Alzheimer's Disease
用于治疗阿尔茨海默病的亲电药物 PED
  • 批准号:
    10230417
  • 财政年份:
    2020
  • 资助金额:
    $ 87.2万
  • 项目类别:
Pro-Electrophilic Drugs PEDs for Alzheimer's Disease
用于治疗阿尔茨海默病的亲电药物 PED
  • 批准号:
    10256731
  • 财政年份:
    2020
  • 资助金额:
    $ 87.2万
  • 项目类别:
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's Disease
散发性阿尔茨海默病中 S-亚硝基化诱导的翻译后修饰和异常细胞信号转导
  • 批准号:
    9919542
  • 财政年份:
    2017
  • 资助金额:
    $ 87.2万
  • 项目类别:
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's Disease
散发性阿尔茨海默病中 S-亚硝基化诱导的翻译后修饰和异常细胞信号转导
  • 批准号:
    9355868
  • 财政年份:
    2017
  • 资助金额:
    $ 87.2万
  • 项目类别:
Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug Abuse
治疗 HIV 相关神经认知障碍的蛋白质组学新方法
  • 批准号:
    9884749
  • 财政年份:
    2016
  • 资助金额:
    $ 87.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了